Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KDS-1001 in CML with Molecular Residual Disease
NCT04808115Phase 1Withdrawn
- Sponsor
- Duke University
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
Phase 1, open-label, single-arm trial of mbIL21-expanded natural killer cells in Chronic Myeloid Leukemia (CML), sponsored by Duke University. Primary endpoints: Molecular Response at 2 weeks and Safety of KDS-1001 at 2 years. Planned start Dec 2024; status: withdrawn.
02
Drugs
mbIL21-expanded natural killer cells
03
Conditions
Chronic Myeloid Leukemia (CML)
Beyond the preview
Go deeper on NCT04808115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04808115.